The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Acceleron Pharma (Inst); Alliance (Inst); Argenx (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Biodesix (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Conversant Bio (Inst); Daiichi Sankyo (Inst); ECOG (Inst); Elpiscience (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).
 
Terrence Lee Fisher
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Patent author, Vaccinex, Inc.
 
Elizabeth E. Evans
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Inventor on following patents: Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent. U.S. Provisional Patent Application No. 62/473,731 Use of Semaphorin-4D inhibitory molecules in combination with an im (Inst)
 
Crystal L. Mallow
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex (I)
Travel, Accommodations, Expenses - Vaccinex
 
Amber Foster
Employment - Vaccinex
 
Megan Boise
Employment - Vaccinex
Stock and Other Ownership Interests - Vaccinex
 
Ernest Smith
Employment - Vaccinex
Leadership - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - Vaccinex
 
John E. Leonard
Employment - Vaccinex
Leadership - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Travel, Accommodations, Expenses - Vaccinex
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Joseph Thaddeus Beck
No Relationships to Disclose
 
Steven Jeffrey Hager
No Relationships to Disclose
 
Tarek Mekhail
No Relationships to Disclose
 
Nagashree Seetharamu
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Genentech; Mirati Therapeutics; Regeneron; Takeda
 
Megan Baumgart
No Relationships to Disclose
 
Nabil F. Saba
Honoraria - BioNTech; CUE Biopharma; Merck
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Blueprint Medicines; GlaxoSmithKline; Merck; Pfizer
 
Conor Ernst Steuer
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ARMO BioSciences; BerGenBio; Caris Life Sciences; Lilly; Mirati Therapeutics; Sanofi/Regeneron
Research Funding - Daiichi Sankyo; Infinity Pharmaceuticals; Seagen; Vaccinex
 
Douglas Adkins
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Coherus Biosciences; CUE Biopharma; Eisai Europe; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Exelixis (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst); Vaccinex (Inst)
 
Barbara Burtness
Consulting or Advisory Role - ALX Oncology; CUE Biopharma; Debiopharm Group; Exelixis; Genentech/Roche; IO Biotech; Ipsen; Kura Oncology; Macrogenics; Maverick Therapeutics; Merck; Merck KGaA; Nanobiotix; PPD Global; Rakuten Medical
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - AstraZeneca; CUE Biopharma (Inst); Eisai; Exelixis (Inst); Genentech; Kura Oncology; Merck; Merck (Inst); Nektar; Rakuten Medical
Travel, Accommodations, Expenses - Debiopharm Group; Merck
 
Maurice Zauderer
Employment - Vaccinex
Leadership - Vaccinex
Stock and Other Ownership Interests - Vaccinex
Patents, Royalties, Other Intellectual Property - inventor on several patents assigned to Vaccinex, Inc. No royalty or other direct financial interest in patent.